BCI-Sonics Secures Hundreds of Millions in Angel and Angel+ Funding Led by Matrix Partners China

Jun 08, 2026 12:21 CST Updated 12:21

BCI-Sonics

Developer of AI Ultrasound Brain-Computer Interface and Non-Invasive Neuromodulation Therapeutic Devices

Review

Recently, the new generationBCI-Sonics, an AI-powered ultrasound brain-computer interface company, has completed its angel and angel+ funding rounds, raising hundreds of millions of RMB. The angel round was led by Matrix Partners China. The funds raised will be used to advance the company's technology validation and industrial implementation.

Jingwei Perspectives

Matrix Partners China asThe lead investor in BCI-Sonics is the largest external institutional investor. Matrix Partners ChinaYang Yi, a senior investment manager at Investment Deep, stated: "Compared to traditional implantable solutions, low-intensity focused ultrasound (LIFU technology offers advantages in both stimulation depth and spatial resolution, enabling non-invasive stimulation and significantly expanding the boundaries from clinical treatment to consumer health. The company’s core team has established strong technical barriers in underlying algorithms and transducer manufacturing processes. Its products not only hold a first-mover advantage in academia but also demonstrate robust engineering implementation capabilities in the fields of general medical AI and neurological rehabilitation. We look forward to partnering with the company to jointly define the “next decade” in brain science.

Financing News

BCI-Sonics was established in Shanghai and positioned as a new generationAI Ultrasound Brain-Computer Interface Company, specializing in "deep, non-invasive, personalized" brain-computer interface technology. The company focuses on deeply integrating AI algorithms, transcranial focused ultrasound (tFUS-LIFU), and multimodal neural reading/decoding technologies, striving to create a next-generation ultrasound brain-computer interface platform that is non-invasive, closed-loop, precise, and offers whole-brain coverage.

Key Technologies for Clinical Efficacy of tFUS: Transcranial Phase Correction

InIn tFUS-LIFU technology, the true engineering challenge lies not merely in “delivering ultrasound into the brain,” but in accurately focusing the acoustic field on the target brain region after penetrating the skull. Significant individual variations exist in human skull thickness, density, curvature, and sound speed distribution. During transcranial propagation, ultrasound inevitably suffers from phase distortion, energy attenuation, and focal shift. If effective transcranial phase compensation is not implemented,TheoryA deviation will occur between the target and the actual focal position of the acoustic field, thereby affecting treatment efficacy and dosage.Consistencyand the reproducibility of clinical outcomes. Therefore, transcranial phase correction technology constitutestFUS: From Basic Research to Verifiable Efficacy and OperableCopyas well as the key technical barriers to the pre-commercialization of the device.

Addressing this critical bottleneck, BCI-Sonics has developed a proprietary transcranial phase correction algorithm that enables rapid individualized calibration and quick compensation for skull-induced acoustic field distortions, thereby enhancing transcranial focusing precision (down to1.5 mm) and stimulation efficacy. The system the company is developing，It is the first quasi-commercial ultrasound brain-computer interface system in China to be equipped with a transcranial phase correction algorithm.

AI Closed-Loop Neuromodulation Platform

The company has established“A stimulation system for synergistic modulation of ‘deep nuclei + superficial cortex,’ which, leveraging dual-modal real-time monitoring via high-precision brain region signals and passive cavitation detection (PCD), achieves quantifiable dose feedback. Building on this, real-time identification of brain states is performed through multi-modal data fusion and AI algorithms to automatically generate personalized stimulation protocols, thereby establishing a ‘”Read—Understanding—Regulation—Feedback—Re-optimization” complete closed-loop neuromodulation system. The company’s long-term goal is not to develop standalone stimulation devices, but to establish an AI-powered, non-invasive brain-computer interface operating system that covers the entire brain and evolves sustainably.

Advancing from the Laboratory to Real-World Validation

The company believes that the industrialization of brain-computer interfaces (BCIs) cannot remain at the conceptual level but must simultaneously meet three conditions: the underlying technology must have a physics and physiology foundation that withstands verification; the devices must achieve a maturity level characterized by engineering standardization and scalable reproducibility; and the clinical pathways must be sufficiently clear to allow for continuous validation in real-world medical settings. Guided by this logic, BCI-Sonics has currently joined hands with numerous renowned universities, Grade A tertiary hospitals, and clinical expert teams to carry out in-depth collaboration, inUnderlying Acoustic TechnologyNeuromodulationMechanism, Multimodal Data Acquisition, Clinical ProtocolsDesignand advancing comprehensively across dimensions such as real-world data validation, with a focus on pain management and addiction intervention,Neural Remodelingand other core areas, jointly design research pathways and validate clinical value, accelerating the transition of technology fromResearch PrototypeBridging the Gap to Preclinical Applications.

Creating the BesttFUS Multidisciplinary Team

BCI-Sonics was founded by Dr. Li Xin, a serial entrepreneur, atFounded in 2025. Dr. Li Xin holds a Ph.D. in Biomedical Engineering from a joint program between the Chinese Academy of Sciences and the Fraunhofer IGD Institute in Germany, and has previouslyRenHead of GE Healthcare's Global R&D Center, China Region, and subsequently founded multiple innovative technology and healthcare enterprises, accumulating extensive experience in the fields of medical imaging, artificial intelligence, brain-computer interfaces, and industrial translation.

The company’s core team comprises professionals from top-tier domestic and international institutions, including Tsinghua University, Imperial College London, Shanghai Jiao Tong University, and Zhejiang University. Their expertise spans multiple disciplines, such as neuroscience, acoustic engineering, medical imaging, artificial intelligence, advanced materials, clinical translation, medical device R&D, and commercialization. Team members possess combined experience in R&D, engineering, and clinical market practice, with deep understanding of fundamental scientific principles and proficiency in the full lifecycle management of medical devices—from concept validation, engineering development, and clinical trials to regulatory approval.Process。

What sets this team apart is that, prior to launching their startup, they had already reached a consensus on the same technological direction, industry assessment, and long-term mission. In other words, the team, vision, technological reserves, and clinical insights were aligned first, before formally initiating the entrepreneurial and fundraising processes.

Regarding the future, Li Xin, founder of BCI-Sonics, stated:“The next decade of brain science will belong to platforms that can truly close the loop between ‘decoding the brain’ and ‘precise intervention.’ Ultrasound is currently one of the few physical modalities with the potential to combine non-invasiveness, deep-brain accessibility, and high spatiotemporal resolution, while AI gives us, for the first time, the opportunity to decode neural activity in real time and dynamically adjust neuromodulation strategies accordingly. The ultimate goal of BCI-Sonics has never been merely a device, but rather a whole-brain-covering, self-evolving operating system for neuromodulation.”